AUM302 continues to demonstrate positive pre-clinical data

Singapore, 13 September 2019 – New pre-clinical data on AUM Biosciences’ PIM/PI3K/mTOR inhibitor, AUM302, was recently presented at the 20th World Conference on Lung Cancer (WCLC) in Barcelona, Spain. The data presented demonstrated that PIM kinase is activated in two different mechanisms of resistance to EGFR TKI inhibition in non-small cell lung cancer (NSCLC) cells namely, MET amplification and epithelial to mesenchymal transition (EMT). Both subtypes of resistant cells were sensitive to treatment with AUM302.

Currently, there are five EGFR tyrosine kinase inhibitors (TKI) available for the treatment of EGFR-mutated NSCLC. However, for virtually all patients, resistance is inevitable and disease progression occurs within one to two years of starting a TKI. Thus, the main goal of treatment for EGFR-mutated NSCLC has been to overcome drug resistance.

Third-generation agents show improved response rates and extended median overall survival (OS), with potential to overcome previously untreatable resistance mechanisms. However, acquired resistance mutations and activation of bypass RTK (receptor tyrosine kinase) signalling mechanisms such as MET can mediate primary and secondary resistance to all EGFR TKIs.

AUM302 was effective at decreasing protein kinase phosphorylation, and has the potential to be developed into co-targeting treatment strategies with an EGFR TKI. This may provide a more durable response for patients with an EGFR mutation and help overcome MET amplified EGFR TKI resistance.

This research was led by Dr. Kathy Gately of the Trinity Translational Medicine Institute, Trinity College Dublin and St James’s Hospital, Dublin, Ireland.


About AUM302

AUM302 is the first ‘oral kinase inhibitor’ to uniquely inhibit three critical cancer targets (pan-PIM kinase, pan-PI3K and mTOR inhibition) via a single molecule. Kinase inhibitors are drugs that have played an increasingly prominent role in the treatment of cancer and inhibiting these three targets has been shown to be more effective than inhibiting them alone. AUM Biosciences recently announced a global license agreement with Inflection Biosciences for exclusive worldwide rights to develop, manufacture and commercialise AUM302, the lead candidate of the IBL-300 series of molecules. AUM302 is currently in the pre-clinical stage of development, with activity predicted across a range of cancers. It has been evaluated in over 700 cancer cell lines and has shown potential for clinical development in breast cancer, lung cancer, leukaemia and neuroblastoma.

About AUM Biosciences

AUM Biosciences (AUM) is an oncology-focused Asian biotechnology company committed to developing affordable cancer therapies. Dedicated to unlocking the value in innovation, AUM harnesses the power of precision medicine and digital health to support patients, physicians and partners. AUM focuses on early-stage development of innovative treatment of cancers prevalent in Asia with the potential to address global markets.

Led by a highly-experienced management team with over 100 years of oncology drug development experience combined, AUM develops potent and highly selective therapeutics in oncology, with an aim to change the drug development paradigm by implementing a holistic approach to developing drugs.

Headquartered in Singapore, AUM is strategically positioned to work, partner and collaborate with leading research institutes, clinicians and pharmaceutical companies globally. AUM is the recipient of Frost & Sullivan’s 2019 Asia-Pacific Biotech Entrepreneurial Company of the Year.

For more information, please visit www.aumbiosciences.com or email info@aumbiosciences.com.